Prsonal Profile

Education

1. 08/2014-11/2019 Doctor of Science, School of Applied Chemistry and Engineering(Changchun Institute of Applied Chemistry Chinese Academy of Sciences), University of Science and Technology of China

2. 09/2010-07/2014 Bachelor of Medicine, School of Pharmaceutical, Jilin University

Research Filed and Awards

1. Tumor Rehabilitation

2. Biomedical Polymer Materials

3. Tumor Targeting Delivery

4. Youth Fund of The National Natural Science Foundation of China, Project Leader

Recent Publications and Presentations

1. Jian Jiang^#, Na Shen^#, Tianyuan Ci, Zhaohui Tang*, Zhen Gu*, Gao Li, and Xuesi Chen*, Combretastatin A4 nanodrug-induced MMP9-amplification boosts tumor-selective release of doxorubicin prodrug, Adv. Mater., 2019, e1904278.

2. Jian Jiang, Na Shen, Wantong Song, Zhaohui Tang*, Gao Li, Combretastatin A4 nanodrug combined plerixafor for inhibiting tumor growth and metastases simultaneously, Biomater. Sci., 2019, 7(12), 5283-5291.

3. Na Shen, Jian Jiang, Dawei Zhang, Zhaohui Tang* and Xuesi Chen, Bortezomib increase the cancer therapy effecacy of poly(amino acid)-doxorubicin, ACS Biomater. Sci. Eng., 2018, 4(6), 2053-2060.

4. Wantong Song, Zhaohui Tang*, Na Shen, Haiyang Yu, YanjieJia, Dawei Zhang, Jian Jiang, Chaoliang He, Huayu Tian and Xuesi Chen*, Combining disulfiramand poly(L-glutamic acid)-cisplatin conjugates for combating cisplatin resistance, J. Controlled Release, 2016, 10(231), 96–102.

5. Xiaohua Zheng, Lei Wang, Yuyao Guan, Qing Pei, Jian Jiang and Zhi gang Xie*, Integration of metal-organic framework with a photoactive porous-organic polymer for interface enhanced phototherapy, Biomater., 2020, 235, 119792.

6. Yan Gao, Jingyao Dong, Mengmeng Chen, Taiwei Wang, Zhaoyun Yang, Kang He, Yuewei Li, Kai Wang, Jian Jiang*, Shuang Zhang*, Protective effect of low-dose radiation on doxorubicin-induced brain injury in mice. Arch. Biochem. Biophys., 2022, 729, 109390.

7. Mengmeng Chen, Jian Jiang, Junyu Chen, Mengqi Wang, Yaci Lu, Lei Liu,  Lijing Zhao*, Lisheng Wang*, The clinical safety and efficacy of targeted PD-L1 therapy with durvalumab in solid tumors, Curr. drug targets, 2023.